BrainCool AB (publ) – Abstract Oral Mucositis accepted for EBMT 2017 accepted

Posted on Posted in Pressmeddelanden

Press release Lund January 24, 2017

Download as PDF

 

Abstract Oral Mucositis accepted for European Society for Blood and Marrow Transplantation (EBMT 2017) accepted

An abstract within the clinical and scientific development plan of the Cooral System has been accepted to be presented at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2017) taking place on March 26–29 2017 in Marseille, France.

The abstract titled OPTIMAL COOLING TEMPERATURE TO PREVENT ADVERSE EFFECTS OF CHEMOTHERAPEUTIC AGENTS have been accepted for a presentation at the EBMT 2017.

The abstract deals with the optimal temperature which should be achieved to prevent oral mucositis (OM) and is a result of an in vitro study, which is now completed as part of a collaboration with the University of Sheffield.

For further information

Martin Waleij – VD BrainCool AB (publ)
Cellphone:         0733 -93 70 76
E-mail:                martin.waleij@braincool.se          

 

 

Denna information är sådan information som BrainCool AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 24 januari 2017.

 This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on January 24, 2017 .